SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Escalating US-Iran tensions, marked by military strikes and oil supply concerns, are driving intense SPY discussion as the community debates a potential market downturn against resilient "buy the dip" narratives amidst geopolitical uncertainty.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Surging as escalating Middle East tensions, including threats to oil supply routes and facilities, propel the energy sector, Battalion Oil (BATL) is captivating traders who are noting its explosive momentum and discussing potential for a short squeeze due to its low float.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is a top trending stock as escalating Middle East tensions, driven by reported attacks on oil infrastructure and disruption in the Strait of Hormuz, ignite community speculation of a massive price surge and potential short squeeze for this low-float oil play, drawing comparisons to past energy rallies.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid heightened US-Iran conflict, triggering debates over a potential market 'bloodbath' driven by rising oil prices and geopolitical instability. However, many in the community contend that the 'war is priced in,' anticipating another 'V recovery' as dip buyers and algorithmic trading systems demonstrate surprising resilience for tech stocks.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating geopolitical tensions in the Middle East following reported US-Israeli strikes on Iran and subsequent regional retaliation, raising significant concerns about global oil supply disruptions, particularly within the critical Strait of Hormuz. The community is actively discussing a potential surge in crude prices, with many anticipating oil could reach $100 or higher amid fears of a prolonged conflict and a short squeeze in the energy sector.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Heightened geopolitical tensions impacting global LNG supply routes, coupled with strong anticipation for its upcoming earnings, are driving significant conversation around Venture Global. The community is actively discussing the company's rapid production expansion, perceived undervaluation relative to peers, and the potential for a substantial short squeeze.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is seeing increased attention amid escalating geopolitical events in the Middle East, with the community actively discussing a potential short squeeze fueled by its high short interest and strategic position in defense technology, particularly its deep ties to Israeli defense programs and participation in key U.S. drone initiatives.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is seeing a dramatic surge driven by a strong earnings beat and highly ambitious revenue guidance for its AI-focused 800G/1.6T data center transceivers. The community is intensely debating whether this marks a legitimate re-rating and short squeeze due to massive industry demand, or if it's an overhyped run susceptible to an announced stock offering and the company's past execution challenges.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending amid escalating geopolitical tensions in the Middle East, with reports of attacks on oil facilities and threats to critical shipping routes like the Strait of Hormuz driving intense community discussion about a potential surge in crude oil prices and significant upside for integrated energy majors.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending amid community anticipation of surging crude oil prices due to heightened Middle East geopolitical tensions, complemented by its strategic positioning for expanded Venezuela production and negotiations for a major Iraq oilfield.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cingulate (NASDAQ:CING) CEO Shane Schaffer Purchases 6,809 Shares

Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer acquired 6,809 shares of the company's stock in a transaction dated Friday, February 6th. The stock was acquired at an average cost...

Cingulate (NASDAQ:CING) CFO Jennifer Callahan Purchases 4,864 Shares

Cingulate Inc. (NASDAQ:CING - Get Free Report) CFO Jennifer Callahan purchased 4,864 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...

Shane Schaffer Buys 6,809 Shares of Cingulate (NASDAQ:CING) Stock

Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer purchased 6,809 shares of Cingulate stock in a transaction that occurred on Friday, February 6th. The stock was bought at an average...

Peter Werth Purchases 19,455 Shares of Cingulate (NASDAQ:CING) Stock

Cingulate Inc. (NASDAQ:CING - Get Free Report) Director Peter Werth acquired 19,455 shares of the company's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...

Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and reaffirmed a ‘Buy’ rating.&nbsp;<a href="https://stocktwits.com/symbol/CING">Cingulate Inc.’s stock</a> snapped a two-day losing streak, rising 2.5% to $4.15 on Tuesday, and added another 1.6% in after-hours trading.The firm said the FDA’s acceptance of Cingulate’s application for its ADHD drug CTx-1301 signals confidence in the treatment’s safety and effectiveness for both children and adults.Roth analysts said the absence of an Advisory Committee review, an earlier-than-expected PDUFA date of May 31, 2026, and a potentially broad label across ADHD patients all strengthen the investment case for Cingulate. They also highlighted the strong approval track record of ADHD stimulants as supportive of the drug’s prospects.The FDA’s acceptance marks a major step forward for CTx-1301, which uses Cingulate’s proprietary Precision Timed Release technology to deliver once-daily, all-day symptom control. The company said Phase 3 data showed rapid onset and sustained efficacy with no serious safety issues reported.The company called the FDA acceptance a “defining milestone”, positioning Cingulate to transition from a development-stage to a commercial-stage company in 2026, pending approval. The firm said commercial preparations are already underway through partnerships with Bend Bio Sciences and Indegene to ensure manufacturing scale-up and market readiness.On Stocktwits, retail sentiment for Cingulate was ‘bullish’ amid an 820% surge in 24-hour message volume.One bullish user highlighted the advantages of Cingulate’s regulatory route, noting it follows a faster and less expensive path typically used for drugs that build on existing approvals with new delivery methods. They noted the company’s silence on social media could hint at buyout interest and said they would only part with their shares for $27.<stembedurl>https://stocktwits.com/StockGuru320/message/632269303</stembedurl>Another bullish user noted that, with the NDA now accepted, the real question for investors was the risk they were taking by not owning the stock at this stage. They added that long-term holders were feeling more confident than ever about the company’s direction.<stembedurl>https://stocktwits.com/Duke1979/message/632260917</stembedurl>Cingulate’s stock has declined 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate’s stock (CING) has declined 16% so far in 2025. (Photo credit: Getty Images)

Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential

Roth Capital said the FDA’s acceptance shows strong confidence in Cingulate’s ADHD drug, adding that its early PDUFA date and clean regulatory path make it a good investment.

Equity

Retail chatter around Cingulate spiked Tuesday after Phase 3 data confirmed that its lead candidate, CTx-1301, significantly improved ADHD symptoms in pediatric patients within five weeks of treatment.At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading.According to the Kansas-based biotech, children who took CTx-1301 at doses of 18.75 mg, 25 mg, and 37.5 mg experienced significant reductions in their ADHD-RS-5 scores.Dr. Raul Silva, chief science officer at Cingulate, revealed the possibility of CTx-1301 becoming a primary treatment option for ADHD after demonstrating effect sizes between 0.737 and 1.185, which surpass the industry standard of 0.73 for long-duration stimulants.CEO Shane Schaffer identified the findings as a “significant value inflection point” while confirming that the company plans to file a New Drug Application (NDA) this summer.CTx-1301 uses Cingulate’s Precision Timed Release platform to provide a single daily dose, which begins working in the morning and maintains effectiveness throughout the day.After receiving FDA approval, the company plans to offer eight different dosage strengths to address the pediatric and adult ADHD markets.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,700% surge in 24-hour message volume.One user highlighted the forthcoming FDA submission as a key milestone and suggested that the recent decline in share price may offer a buying opportunity.&nbsp;<stembedurl>https://stocktwits.com/Duke1979/message/615297512</stembedurl>Another user was more cautious, noting that the effect size observed in the pediatric trial appeared lower than earlier projections. However, they acknowledged that sustained efficacy throughout the day could remain a key differentiator.<stembedurl>https://stocktwits.com/TheSterl/message/615215732</stembedurl>The stock has declined 29% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric Efficacy

Phase 3 data showed the company’s ADHD drug, CTx-1301, significantly improved symptoms in children within five weeks. The company plans to file for FDA approval this summer.

Cingulate Inc.'s shares generated heightened retail chatter on Wednesday after receiving the FDA's pre-New Drug Application (NDA) meeting minutes for its primary asset CTx-1301 that targets ADHD with a daily stimulant treatment.Cingulate shares rose 8.7% to close at $4.25 on Tuesday but slipped 4.2% to $4.07 in after-hours trading.Following a pre-NDA meeting on April 2, the company confirmed that it will submit an NDA for CTx-1301 in the summer of 2025 based on the FDA’s feedback.&nbsp;The formulation CTx-1301 contains dexmethylphenidate and employs Cingulate’s Precision Timed Release technology to provide three doses during specific times of the day.&nbsp;The technology aims to overcome the problem of reduced effectiveness in existing stimulant treatments during the afternoon hours.The FDA minutes confirmed that the existing nonclinical safety data sufficiently support the NDA submission.The agency entered into a post-approval agreement with Cingulate to gather stability data for six intermediate dose strengths, spanning from 12.5 mg to 43.75 mg.The regulatory body recognized a scientific connection to Focalin XR, which permitted Cingulate to benefit from existing data on drug effectiveness and safety.&nbsp;The agency found the company’s integrated safety and efficacy summary approaches reasonable.One user said the stock could reach $6, citing a sharp spike to $5.16 as a signal of potential upward momentum.&nbsp;On Stocktwits, retail sentiment was ‘bullish’ amid a 1,600% surge in 24-hour message volume.<stembedurl>https://stocktwits.com/doublenickels55/message/614579894</stembedurl>Another user highlighted the absence of negative news and reaffirmed confidence in the NDA timeline, noting the company remains on track for a summer submission.<stembedurl>https://stocktwits.com/fullobullz/message/614577626</stembedurl>The stock has declined 16.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug

CTx-1301 employs its Precision Timed Release system to administer three doses of dexmethylphenidate throughout the day for managing ADHD symptoms.

<a href="https://stocktwits.com/symbol/CING">Cingulate Inc</a>. (CING) shares skyrocketed over 85% in pre-market trading on Friday, becoming the top trending stock on Stocktwits. The surge comes after the stock rallied nearly 160% on Thursday, triggered by the company's announcement of a European patent for its ADHD drug candidate, CTx-1301.This patent expands Cingulate's intellectual property protection to include up to 30 European countries, adding to its existing patents in Australia, Canada, and Israel. The company is also pursuing patents in Hong Kong, South Korea, and the United States.ADHD is a significant global health issue, affecting millions worldwide. Cingulate's focus on developing treatments for ADHD aligns with its broader strategy of utilizing its proprietary PTR technology for other therapeutic areas, such as anxiety disorders.The patent news has injected a much-needed dose of optimism into the stock, which has lost over 94% of its value this year due to several headwinds.The company reported disappointing Q2 earnings and has been grappling with financial challenges, including a significant cash burn and a history of top executive departures.Cingulate has a cash balance of just $0.4 million as of June 30, 2024. To address this, the company raised $1.6 million in July through warrant inducement and plans to seek additional funding.A regulatory filing last year warned of potential bankruptcy if financial issues persisted.<stembedurl>https://stocktwits.com/SelectiveTrader/message/583139933</stembedurl>Despite these challenges, the European patent news has reignited interest in Cingulate. However, it remains to be seen if this momentum can be sustained and if the company can successfully navigate its financial hurdles to capitalize on its drug development pipeline. &nbsp;

ADHD is a significant global health issue, affecting millions worldwide. Image via Vecteezy

Cingulate Stock Is Hottest Talk Of Retail Street After Europe Patent For ADHD Drug Candidate

Retail investors, buoyed by the news, are actively discussing the stock on Stocktwits. However, some remain cautious due to the company's troubled history and ongoing financial challenges.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CING News

CINGCingulate Inc